Fig. 5: GSK5959 inhibited HCC development in vitro and in vivo.
From: Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer
a GSK5959 is a BRPF1-specific inhibitor. b, c Treatment with 10 μM GSK5959 significantly reduced cell colony formation and cell proliferation in multiple HCC cell lines. d BRPF1 expression was positively correlated with Ki67 expression in TCGA HCC cohort (R2 = 0.1629, P < 0.0001, linear regression). e Displays of mice treated with mock (DMSO) or GSK5959 (30 mg/kg) via intraperitoneal injection once a day for 2 weeks and isolated subcutaneous tumors in the order of decreasing size. f The tumor volume and weight in the GSK5959 treatment group were significantly lower than those in the control group. n = 8 Error bars indicate mean ± SD. Data were compared by independent t-test unless indicated otherwise. Results were repeated at least three times. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. mock as indicated.
